OSTEOTECH GRAFTON DRIVES REVENUE GROWTH IN 1997 WITH 74% U.S. SALES INCREASE; KENSEY NASH BREAKS EVEN ON ANGIO-SEAL ROYALTY STREAM IN SECOND QUARTER
This article was originally published in The Gray Sheet
Executive Summary
A 74% domestic sales increase for Osteotech's flagship Grafton demineralized bone matrix product in 1997 to $34.9 mil. led the company to a solid financial performance in the three and 12-month periods ended Dec. 31., as revenues increased 34% to $12.2 mil. and 28% to $36 mil. for the quarter and year, respectively.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.